GB1211
- Generic Name
- GB1211
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16BrF3N4O4S
- CAS Number
- 1978336-95-6
- Unique Ingredient Identifier
- 94EN2E6BLW
- Background
GB1211 is an orally active galectin-3 (Gal-3) inhibitor.
- Associated Conditions
- -
- Associated Therapies
- -
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 92
- Registration Number
- NCT05913388
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
A Study to Compare Pharmacokinetics of GB1211
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 13
- Registration Number
- NCT05747573
- Locations
- 🇳🇱
QPS Netherlands BV, Groningen, Netherlands
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 88
- Registration Number
- NCT05240131
- Locations
- 🇫🇷
CHRU, Tours, France
🇵🇱Samodzielny Publiczny Zespol Gruzlicy I Chorob Pluc, Olsztyn, Poland
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 54
- Registration Number
- NCT05009680
- Locations
- 🇧🇬
University Multiprofile Hospital, Clinic of gastroenterology, Sofia, Оborishte District, Bulgaria
🇧🇬COAMC Medical, Sofia, Bulgaria
🇧🇬Gastroenterology Clinic, Lozenets district, Sofia, Bulgaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Galecto Biotech AB
- Registration Number
- NCT04607655
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 78
- Registration Number
- NCT03809052
- Locations
- 🇬🇧
(For Parts A and B) Covance Clinical Research Unit Ltd, Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath